Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-Line Antibiotics against Multidrug-Resistant Gram-Negative Bacteria

ACS Infectious Diseases

Volumn 1, Issue 11, 2016, Pages 568-575

  Roberts, Kade D ^a   Azad, Mohammad A K ^a   Wang, Jiping ^a   Horne, Andrew S ^a   Thompson, Philip E ^a   Nation, Roger L ^a   Velkov, Tony ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

colistin; Gram negative bacteria; multidrug resistance; nephrotoxicity; polymyxin

Indexed keywords

COLISTIN; LIPOPEPTIDE; POLYMYXIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; APOPTOSIS; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PROXIMAL TUBULE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 84963726294     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.5b00085     Document Type: Article

References (46)

1. Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E., and Li, J. (2013) Pharmacology of polymyxins: new insights into an 'old' class of antibiotics Future Microbiol. 8, 711-724 10.2217/fmb.13.39
2. Landman, D., Georgescu, C., Martin, D. A., and Quale, J. (2008) Polymyxins revisited Clin. Microbiol. Rev. 21, 449-465 10.1128/CMR.00006-08
3. Benedict, R. G. and Langlykke, A. F. (1947) Antibiotic activity of Bacillus polymyxa J. Bacteriol. 54, 24
4. Stansly, P. G., Shepherd, R. G., and White, H. J. (1947) Polymyxin: a new chemotherapeutic agent Bull. Johns Hopkins Hosp. 81, 43-54
5. Ainsworth, G. C., Brown, A. M., and Brownlee, G. (1947) Aerosporin, an antibiotic produced by Bacillus aerosporus Greer Nature 160, 263 10.1038/160263a0
6. Koch-Weser, J., Sidel, V. W., Federman, E. B., Kanarek, P., Finer, D. C., and Eaton, A. E. (1970) Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy Ann. Intern. Med. 72, 857-868 10.7326/0003-4819-72-6-857
7. Brown, J. M., Dorman, D. C., and Roy, L. P. (1970) Acute renal failure due to overdosage of colistin Med. J. Aust. 2, 923-924
8. Price, D. J. and Graham, D. I. (1970) Effects of large doses of colistin sulphomethate sodium on renal function Br. Med. J. 4, 525-527 10.1136/bmj.4.5734.525
9. Duncan, D. A. (1973) Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis Minnesota Med. 56, 31-35
10. Boucher, H. W., Talbot, G. H., Benjamin, D. K., Jr., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., and Gilbert, D. (2013) 10 x ′20 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America Clin. Infect. Dis. 56, 1685-1694 10.1093/cid/cit152
11. Zavascki, A. P., Goldani, L. Z., Li, J., and Nation, R. L. (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review J. Antimicrob. Chemother. 60, 1206-1215 10.1093/jac/dkm357
12. Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., and Paterson, D. L. (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections Lancet Infect. Dis. 6, 589-601 10.1016/S1473-3099(06)70580-1
13. Nation, R. L., Li, J., Cars, O., Couet, W., Dudley, M. N., Kaye, K. S., Mouton, J. W., Paterson, D. L., Tam, V. H., Theuretzbacher, U., Tsuji, B. T., and Turnidge, J. D. (2015) Framework for optimization of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus Lancet Infect. Dis. 15, 225-234 10.1016/S1473-3099(14)70850-3
14. Bergen, P. J., Li, J., Rayner, C. R., and Nation, R. L. (2006) Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa Antimicrob. Agents Chemother. 50, 1953-1958 10.1128/AAC.00035-06
15. Hartzell, J. D., Neff, R., Ake, J., Howard, R., Olson, S., Paolino, K., Vishnepolsky, M., Weintrob, A., and Wortmann, G. (2009) Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center Clin. Infect. Dis. 48, 1724-1728 10.1086/599225
16. Kubin, C. J., Ellman, T. M., Phadke, V., Haynes, L. J., Calfee, D. P., and Yin, M. T. (2012) Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy J. Infect. 65, 80-87 10.1016/j.jinf.2012.01.015
17. Akajagbor, D. S., Wilson, S. L., Shere-Wolfe, K. D., Dakum, P., Charurat, M. E., and Gilliam, B. L. (2013) Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center Clin. Infect. Dis. 57, 1300-1303 10.1093/cid/cit453
18. Rigatto, M. H., Behle, T. F., Falci, D. R., Freitas, T., Lopes, N. T., Nunes, M., Costa, L. W., and Zavascki, A. P. (2015) Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study J. Antimicrob. Chemother. 70, 1552-1557 10.1093/jac/dku561
19. Velkov, T., Thompson, P. E., Nation, R. L., and Li, J. (2010) Structure-activity relationships of polymyxin antibiotics J. Med. Chem. 53, 1898-1916 10.1021/jm900999h
20. Orwa, J., Govaerts, C., Busson, R., Roets, E., Van Schepdael, A., and Hoogmartens, J. (2001) Isolation and structural characterization of polymyxin B components J. Chromatogr. A 912, 369-373 10.1016/S0021-9673(01)00585-4
21. Govaerts, C., Orwa, J., Van Schepdael, A., Roets, E., and Hoogmartens, J. (2002) Characterization of polypeptide antibiotics of the polymyxin series by liquid chromatography electrospray ionization ion trap mass spectrometry J. Pept. Sci. 8, 45-55 10.1002/psc.367.abs
22. Van den Bossche, L., Van Schepdael, A., Chopra, S., Hoogmartens, J., and Adams, E. (2011) Identification of impurities in polymyxin B and colistin bulk sample using liquid chromatography coupled to mass spectrometry Talanta 83, 1521-1529 10.1016/j.talanta.2010.11.044
23. Orwa, J., Govaerts, C., Busson, R., Roets, E., Van Schepdael, A., and Hoogmartens, J. (2001) Isolation and structural characterization of colistin components J. Antibiot. 54, 595-599 10.7164/antibiotics.54.595
24. Govaerts, C., Orwa, J., Van Schepdael, A., Roets, E., and Hoogmartens, J. (2002) Liquid chromatography-ion trap tandem mass spectrometry for the characterization of polypeptide antibiotics of the colistin series in commercial samples J. Chromatogr. A 976, 65-78 10.1016/S0021-9673(02)00375-8
25. He, J., Ledesma, K. R., Lam, W. Y., Figueroa, D. A., Lim, T. P., Chow, D. S., and Tam, V. (2010) Variability of polymyxin B major components in commercial formulations Int. J. Antimicrob. Agents 35, 308-310 10.1016/j.ijantimicag.2009.11.005
26. Brink, A. J., Richards, G. A., Colombo, G., Bortolotti, F., Colombo, P., and Jehl, F. (2014) Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics Int. J. Antimicrob. Agents 43, 1-6 10.1016/j.ijantimicag.2013.06.013
27. He, H., Li, J. C., Jacob, J., Chen, G., Lee, H. J., Tsuji, B. T., Thompson, P. E., Roberts, K. D., Velkov, T., and Li, J. (2013) Pharmacokinetics of four different brands of colistimethate and formed colistin in rats J. Antimicrob. Chemother. 68, 2311-2317 10.1093/jac/dkt207
28. Tam, V. H., Cao, H., and Hu, M. (2011) In vitro potency of various polymyxin B components Antimicrob. Agents Chemother. 55, 4490-4491 10.1128/AAC.00119-11
29. Dudhani, R. V., Turnidge, J. D., Nation, R. L., and Li, J. (2010) fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models J. Antimicrob. Chemother. 65, 1984-1990 10.1093/jac/dkq226
30. Garonzik, S. M., Li, J., Thamlikitkul, V., Paterson, D. L., Shoham, S., Jacob, J., Silveira, F. P., Forrest, A., and Nation, R. L. (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients Antimicrob. Agents Chemother. 55, 3284-3294 10.1128/AAC.01733-10
31. Li, J., Rayner, G. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., and Liolio, L. (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii Antimicrob. Agents Chemother. 50, 2946-2950 10.1128/AAC.00103-06
32. Dubrovskaya, Y., Chen, T.-Y., Scipione, M. R., Esaian, D., Phillips, M. S., Papadopoulos, J., and Mehta, S. A. (2013) Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections Antimicrob. Agents Chemother. 57, 5394-5397 10.1128/AAC.00510-13
33. Azad, M. A., Finnin, B. A., Poudyal, A., Davis, K., Li, J., Hill, P. A., Nation, R. L., and Velkov, T. (2013) Polymyxin B induces apoptosis in kidney proximal tubular cells Antimicrob. Agents Chemother. 57, 4329-4335 10.1128/AAC.02587-12
34. Li, J., Milne, R. W., Nation, R. L., Turnidge, J. D., Smeaton, T. C., and Coulthard, K. (2003) Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration Antimicrob. Agents Chemother. 47, 1766-1770 10.1128/AAC.47.5.1766-1770.2003
35. Zavascki, A. P., Goldani, L. Z., Cao, G., Superti, S. V., Lutz, L., Barth, A. L., Ramos, F., Boniatti, M. M., Nation, R. L., and Li, J. (2008) Pharmacokinetics of intravenous polymyxin B in critically ill patients Clin. Infect. Dis. 47, 1298-1304 10.1086/592577
36. Azad, M. A., Roberts, K. D., Yu, H. H., Schofield, A. V., James, S. A., Howard, D. L., Nation, R. L., Rogers, K. L., De-Jonge, M. D., Thompson, P. E., Fu, J., Velkov, T., and Li, J. (2015) Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach Anal. Chem. 87, 1590-1595 10.1021/ac504516k
37. Azad, M. A., Atker, J., Rogers, K. L., Nation, R. L., Velkov, T., and Li, J. (2015) Major pathways of polymyxin-induced apoptosis in rat kidney proximal tubular cells Antimicrob. Agents Chemother. 59, 2136-2143 10.1128/AAC.04869-14
38. Keirstead, N. D., Wagoner, M. P., Bentley, P., Blais, M., Brown, C., Cheatham, L., Ciaccio, P., Dragan, Y., Ferguson, D., Fikes, J., Galvin, M., Gupta, A., Hale, M., Johnson, N., Luo, W. L., McGrath, F., Pietras, M., Price, S., Sathe, A. G., Sasaki, J. C., Snow, D., Walsky, R. L., and Kern, G. (2014) Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers Toxicol. Sci. 137, 278-291 10.1093/toxsci/kft247
39. Vaara, M. and Vaara, T. (2013) The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells Int. J. Antimicrob. Agents 41, 292-293 10.1016/j.ijantimicag.2012.10.005
40. Nord, N. M. and Hoeprich, P. D. (1964) Polymyxin B and colistin. A critical comparison N. Engl. J. Med. 270, 1030-1035 10.1056/NEJM196405142702002
41. Yousef, J. M., Chen, G., Hill, P. A., Nation, R. L., and Li, J. (2011) Melatonin attenuates colistin-induced nephrotoxicity in rats Antimicrob. Agents Chemother. 55, 4044-4049 10.1128/AAC.00328-11
42. Magee, T. V., Brown, M. F., Starr, J. S., Ackley, D. C., Abramite, J. A., Aubrecht, J., Butler, A., Crandon, J. L., Dib-Hajj, F., Flanagan, M. E., Granskog, K., Hardink, J. R., Huband, M. D., Irvine, R., Kuhn, M., Leach, K. L., Li, B., Luke, D. R., MacVane, S. H., Miller, A. A., McCurdy, S., McKim, J., J, M., Nicolau, D. P., Nguyen, H., Noe, M. C., O'Donnell, J. P., Seibel, S. B., Shen, Y., Stepan, A. F., Tomaras, A. P., Wilga, P. C., Zhang, L., Xu, J., and Chen, J. M. (2013) Discovery of dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections J. Med. Chem. 56, 5079-5093 10.1021/jm400416u
43. British Pharmacopoeia Comission. (2014) British Pharmacopeia, Stationary Office, London, UK.
44. European Pharmacopoeia Commission. (2014) European Pharmacopoeia, 8 th ed., Council of Europe, Strasbourg, France.
45. United States Pharmacopeial Convention. (2015) United States Pharmacopoeia 36: National Formulary 31, United States Pharmacopeial Convention, Inc., Rockville, MD, USA.
46. Clinical and Laboratory Standards Institute. (2013). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. M100-S23. Wayne, PA, USA.